Oxford Drug Design and PhoreMost collaborate to advance novel cancer therapeutics discovery
Targeted protein degradation discovery programme to harness artificial intelligence to identify new E3 Ligase-based therapeutic strategies. Oxford Drug Design, a biotechnology company […]
Oxford Drug Design appoints Dr Richard Cooper as Head of Machine Learning and Prof. Xiang-Lei Yang to its Scientific Advisory Board
Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering AI platform to develop novel molecules for use in cancer […]
Dr Aras Asaad presents at the 5th Artificial Intelligence in Chemistry Symposium
Dr Aras Asaad presented his work in exploiting existing 2D image-based deep learning architectures to capture 3D molecular information at this year’s […]
Prof. W. Graham Richards on the origins of the Journal of the Molecular Graphics and Modelling Society
Oxford Drug Design’s Founder and current Chairman, Prof. W. Graham Richards CBE FRS has recently written an account of the origins of […]
Oxford Drug Design attending the 28th tRNA Conference 2022
Paul Finn, CSO, will be attending the 28th tRNA Conference, 12-16 June 2022 in Columbus, Ohio, USA. On 13 June at 4:45pm […]
Oxford Drug Design receives $2.7 (£2.2) million in bridge round commitments
Oxford Drug Design Limited (ODD), a biotechnology company with a proprietary computational and machine learning platform, has raised $2.7M (£2.2M) in funding […]
Oxford Drug Design to Present at ASM Microbe 2022
Paul Finn, CSO, will be attending ASM Microbe 2022, 9-13 June in Washington D.C. USA and making an Oral Presentation on Saturday […]
Dr. Grace Edmund presents at ICARe
Dr. Grace Edmund was selected to attend the Interdisciplinary Course on Antibiotics and Resistance (ICARe) hosted by Les Pensières Center for Global […]
Oxford Drug Design attends the CARTNET Symposium
Marco Albanese recently presented his work in designing novel histidine kinases inhibitors at the CARTNET Symposium in Valencia. He described using Oxford […]
Oxford Drug Design welcome new CEO Dr. Alan D. Roth
Oxford Drug Design Board of Directors announces the appointment of Dr. Alan D. Roth Chief Executive Officer, effective immediately. Alan takes over […]
Oxford Drug Design at virtual conferences
Oxford Drug Design recently attended both the virtual 3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry and UK-QSAR Autumn 2020 meetings. Dr […]
Prof. Graham Richards speaks to Biospring
Prof. Graham Richards recently spoke to Dr. Michelle Dipp, Co-Founder and Managing Partner of Biospring, on the topic of computer-aided molecular design.